Biologic Prescription Patterns and Biomarker Determinants of First‐Line Dupilumab in Danish Adult Patients With Severe Asthma and Comorbid Atopic Dermatitis
Clinical & Experimental Allergy2025Vol. 55(12), pp. 1208–1218
Citations Over TimeTop 10% of 2025 papers
Marianne Baastrup Soendergaard, Kjell Erik Julius Håkansson, Susanne Hansen, Anne‐Sofie Bjerrum, Johannes Martin Schmid, Sofie Lock Johansson, Linda Makowska Rasmussen, Barbara Bonnesen, Roxana Vijdea, Anna von Bülow, Niels Steen Krogh, Ole Hilberg, Simon Francis Thomsen, Charlotte Suppli Ulrik, Celeste Porsbjerg
Abstract
Biologic prescription patterns in severe asthma vary according to comorbid atopic dermatitis status. In patients with comorbid atopic dermatitis, elevated IgE predicts first-line dupilumab prescription, indicating that the severity of atopic dermatitis influences treatment decisions. Additional research is needed to explore the management of coexisting T2 diseases with biological therapies.
Related Papers
- Dupilumab, A Monoclonal Antibody for Atopic Dermatitis: A Review of Current Literature.(2016)
- → Lebrikizumab Improves Atopic Dermatitis and Quality of Life in Patients With Moderate-to-Severe Atopic Dermatitis Previously Treated With Dupilumab: Results From the ADapt Trial(2025)5 cited
- → Case report of the dupilumab applying in atopic dermatitis child(2021)1 cited
- → The Use of Dupilumab in Severe Atopic Dermatitis During Pregnancy: A Case Report(2021)1 cited
- → A Systemic Review of Dupilumab Efficacy and Safety by Phenotypic Variations of Atopic Dermatitis(2021)